64
Participants
Start Date
April 30, 2010
Primary Completion Date
August 31, 2011
Study Completion Date
December 31, 2012
ENMD-2076
275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
Indiana University Simon Cancer Center, Indianapolis
University of Chicago Medical Center, Chicago
University of Colorado Cancer Center, Aurora
Dana Farber/Partners Cancer Care, Boston
Memorial Sloan-Kettering Cancer Center, New York
Princess Margaret Hospital, Toronto
Lead Sponsor
CASI Pharmaceuticals, Inc.
INDUSTRY